Independent Data Monitoring Committee Recommends Early Stopping of Phase 3 Study of Ibrutinib in Relapsed/Refractory CLL/SLL Patients Based on a Planned Interim Analysis
- EMEA Innovative Medicine
- Independent Data Committee Recommends Early Stopping of Phase 3 Ibrutinib Study
Independent Data Committee Recommends Early Stopping of Phase 3 Ibrutinib Study
- X (Twitter)
Copy link